On the other hand, at the beginning of the study, 76.3% of the patients (n = 2514) were receiving preventive treatment for stroke: 85% of the patients were taking antiaggregants and 5.9% anticoagulants
[PubMed Central ID: PMC8989414]
It appears the drug manufacturers of G-agonists have no interest in this vital objective, without any ongoing prospective clinical trial efforts directed at cessation of their drugs without reversal of weight gain and assorted benefits
However, they should be kept in their original bottle
however, since then, a higher 7.2 mg dose of Wegovy has been approved, with roughly 19% to 21% weight loss in its own trial, and it has not been compared head-to-head with tirzepatide
Our review critically re-evaluates the role of fibrates, highlighting emerging evidence on their differential effects in MASLD, CKD, and diabetic microvascular complications